Biomaterial considerations for drug-eluting stents.
The ultimate test for implant biomaterials is determined by the long-term, post-market clinical product performance. This is a key consideration in the initial design and development for drug-eluting stents. To insure this ultimate clinical success, a rigorous series of bench-top, preclinical and clinical evaluations must be performed. The factors in the biomaterial choice which are important for each stage in this development process include pharmaceutical, physical, and biological elements. This presentation will outline the steps taken by Boston Scientific in each of these stages to achieve the desired clinical end-points.
Parsonage
Ed
E
Boston Scientific Corporation, Maple Grove, MN 55311, USA.
Girton
Tim
T
Knapp
David
D
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001672:Biocompatible Materials / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D023903:Coronary Restenosis / Q000601:surgery; D016503:Drug Delivery Systems; D015195:Drug Design; D054855:Drug-Eluting Stents; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D018625:Microscopy, Atomic Force; D015607:Stents; D013678:Technology, Pharmaceutical / Q000379:methods
D000893:Anti-Inflammatory Agents; D001672:Biocompatible Materials; D005343:Fibrinolytic Agents